Table 3.
Cut-off value, clinical sensitivity, specificity, and area under the curve for discriminating healthy controls and AD subjects and for differentiating disease severity via ROC curve analysis using biomarker concentrations in human plasma
| Plasma biomarker | Feature | Healthy controls vs. AD subjects | MCI due to AD vs. early-stage AD |
|---|---|---|---|
| Aβ1–42 | Cut-off value | 16.41 pg/mL | 17.68 pg/mL |
| Sensitivity | 0.945 | 0.742 | |
| Specificity | 0.926 | 0.750 | |
| AUC | 0.976 | 0.762 | |
| Tau protein | Cut-off value | 25.20 pg/mL | 37.93 pg/mL |
| Sensitivity | 0.964 | 0.742 | |
| Specificity | 0.956 | 0.792 | |
| AUC | 0.993 | 0.822 | |
| Aβ1–42XTau protein | Cut-off value | 455.49 (pg/mL)2 | 643.96 (pg/mL)2 |
| Sensitivity | 0.945 | 0.774 | |
| Specificity | 0.971 | 0.837 | |
| AUC | 0.995 | 0.841 |
AD subjects include those with MCI due to AD and early-stage AD
AUC area under the curve